In today’s briefing:
- Pre-IPO Shanghai Bao Pharmaceuticals – Future Commercialization Is a Test
- Kissei Pharmaceutical (4547 JP): FY25 Looks Stable; Recent Licensing Deals Key To Near Term Growth
- ACHV: 2Q:25 NDA Submission
- Ainos, Inc: ASE Collaboration Expands AI Nose Opportunity in Smart Manufacturing
- CellSource (4880 JP): Q1 FY10/25 flash update
Pre-IPO Shanghai Bao Pharmaceuticals – Future Commercialization Is a Test
- KJ017 is the first and only recombinant human hyaluronidase to reach NDA stage in China. Bao needs to combine SC Formulations with antibodies. KJ103 may not be a blockbuster variety.
- Considering multiple mature FSH products have been on the market for many years and also been recognized by patients, Bao needs to invest in educating the market/patients to accept SJ02.
- After Series C+ Financing, Post-money valuation reached RMB4.87 billion. However, we think there could be some uncertainties in terms of future commercialization performance of Bao’s three core products.
Kissei Pharmaceutical (4547 JP): FY25 Looks Stable; Recent Licensing Deals Key To Near Term Growth
- Kissei Pharmaceutical (4547 JP) reported 14% YoY jump in revenue during 9MFY25 driven by Beova and Tavneos amidst price revision pressures and generic competition.
- The company has reiterated FY25 guidance of revenue rising 14% YoY, with major drugs witnessing growth.
- Main trigger point happens to be the in-licensing deal and the sub-licensing agreements the company has signed with various players giving an opportunity to expand its market in near future.
ACHV: 2Q:25 NDA Submission
- Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world.
- Topline results from ORCA-2 were reported in April 2022 and for ORCA-3 in May 2023.
- Results exceeded expectations on safety & efficacy parameters.
Ainos, Inc: ASE Collaboration Expands AI Nose Opportunity in Smart Manufacturing
- Broadens AI Nose partnership with leading semiconductor company.
- Ainos entered a strategic collaboration with Advanced Semiconductor Engineering (ASE) to integrate AI Nose into ASE’s semiconductor packaging and testing smart factories.
- AI Nose should further enhance ASE’s fully automated, smart manufacturing facilities with improved air monitoring, AI- predictive maintenance and efficiency, process optimization, and better environmental sustainability.
CellSource (4880 JP): Q1 FY10/25 flash update
- Revenue decreased by 27.6% YoY to JPY849mn, with operating and recurring losses of JPY62mn and JPY61mn, respectively.
- Contract processing services revenue fell 16.4% YoY, with orders declining 12.4% YoY to 4,981 in Q1 FY10/25.
- Medical device sales revenue dropped 26.7% YoY, while cosmetics sales revenue decreased 65.2% YoY in Q1 FY10/25.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
